Neural stem cell (NSC)-based therapies offer potential for neural repair in central nervous system (CNS) inflammatory and degenerative disorders. Typically, these conditions present with multifocal CNS lesions making it impractical to inject NSCs locally, thus mandating optimization of vascular delivery of the cells to involved sites. Here, we analyzed NSCs for expression of molecular effectors of cell migration and found that these cells are natively devoid of E-selectin ligands. Using glycosyltransferase-programmed stereosubstitution (GPS), we glycan engineered the cell surface of NSCs ("GPS-NSCs") with resultant enforced expression of the potent E-selectin ligand HCELL (hematopoietic cell E-/L-selectin ligand) and of an E-selectin-binding glycoform of neural cell adhesion molecule ("NCAM-E"). Following intravenous (i.v.) injection, short-term homing studies demonstrated that, compared with buffer-treated (control) NSCs, GPS-NSCs showed greater neurotropism. Administration of GPS-NSC significantly attenuated the clinical course of experimental autoimmune encephalomyelitis (EAE), with markedly decreased inflammation and improved oligodendroglial and axonal integrity, but without evidence of long-term stem cell engraftment. Notably, this effect of NSC is not a universal property of adult stem cells, as administration of GPS-engineered mouse hematopoietic stem/progenitor cells did not improve EAE clinical course. These findings highlight the utility of cell surface glycan engineering to boost stem cell delivery in neuroinflammatory conditions and Glycobiology, 2015Glycobiology, , vol. 25, no. 12, 1392Glycobiology, -1409 indicate that, despite the use of a neural tissue-specific progenitor cell population, neural repair in EAE results from endogenous repair and not from direct, NSC-derived cell replacement.
Introduction
Nature has developed an extremely efficient mechanism to deliver circulating cells to sites of inflammation and injury. This process is controlled by a highly ordered cascade of molecular interactions (Butcher 1991; Springer 1994; Sackstein 2005) . The first essential event in cell recruitment involves shear-resistant adhesion of flowing cells on the endothelial surface, a process most efficiently mediated by selectins, a family of three Ca 2+ -dependent lectins (comprised of E-, P-and L-selectins), binding to their respective counter-receptors. These interactions initially tether the cell to the vessel wall and, in the context of vascular shear flow, cause the cell to roll along the endothelial surface at velocities below that of the prevailing hemodynamic stream (Step 1). This process facilitates engagement of specific cellborne chemokine receptors to pertinent chemokines present in the perivascular areas, thereby triggering inside-out signal transduction events leading to increased adhesiveness of integrin family members (
Step 2). Adhesive interactions between the activated cell integrins and their cognate endothelial cell counter-receptors then lead to arrest of rolling and firm adhesion of the cell to the vessel wall (Step 3), and, ultimately, transendothelial migration (extravasation, Step 4). In multiple sclerosis (MS), and in its animal model, experimental autoimmune encephalomyelitis (EAE), recruitment of immunologic effectors, is mediated by the upregulation of the vascular selectins, E-and P-selectins. E-and P-selectins are expressed on brain endothelium after in vivo activation with lipopolysaccharide or tumor necrosis factor-α (TNF-α); however, in murine EAE, P-selectin is expressed only transiently (Piccio et al. 2002) . Notably, E-selectin is expressed throughout the inflammatory period with a patchy distribution at sites where vessels branch, suggesting the existence of preferential recruitment areas (Piccio et al. 2002) . E-selectin is also characteristically found in vessels from acute plaques in MS patients (Washington et al. 1994; Lee and Benveniste 1999) . These findings suggest that E-selectin plays a dominant role in the recruitment of circulating cells to the brain in inflammatory diseases.
All three selectins bind to specialized carbohydrate determinants, comprised of sialofucosylations containing an α(2,3)-linked sialic acid substitution on galactose, and an α(1,3)-linked fucose modification on N-acetylglucosamine, prototypically displayed as the terminal tetrasaccharide sialyl Lewis X (sLe x ) (Polley et al. 1991; Sackstein 2005 ). This structure, also known as "CD15s", may be displayed on either a protein scaffold (i.e., a glycoprotein) or a lipid scaffold (i.e., a glycolipid) and is recognized by a monoclonal antibody (mAb) such as CSLEX-1 and HECA-452 (Alon et al. 1995; Fuhlbrigge et al. 1997; Dimitroff et al. 2001; Gadhoum and Sackstein 2008; Merzaban et al. 2011; AbuSamra et al. 2015) . Although additional structural modifications principally involving sulfation increase binding affinity of P-and L-selectins to sLe
x , no such modifications are needed for optimal binding of E-selectin (Leppanen et al. 2000; Rosen 2004 ). Neural stem cell (NSC)-based therapy has generated great hope for halting and/or reversing disease progression in central nervous system (CNS) inflammatory and/or degenerative diseases (Ben-Hur et al. 2003; Pluchino et al. 2003 Pluchino et al. , 2005 Imitola, Raddassi, et al. 2004; Einstein et al. 2006 Einstein et al. , 2007 Ziv et al. 2006; Lee et al. 2008) . It is well known that NSCs express Step 2 and Step 3/4 effectors, such as CXCR4 (Flax et al. 1998; Bezzi et al. 2001; Imitola, Raddassi, et al. 2004 ) and VLA-4 (Pluchino et al. 2005; Rampon et al. 2008) , respectively, but there are no data on whether NSCs natively express Step 1 effectors. Accordingly, we examined expression of Step 1 effectors on mouse NSCs and found that these cells are conspicuously devoid of
Step 1 effectors, in particular, E-selectin ligands. Using the EAE model, we analyzed whether enforced E-selectin ligand activity via cell surface glycan engineering would impact migration of administered NSCs and, more importantly, the therapeutic effect(s) of administered cells. To this end, we utilized a technology called glycosyltransferase-programmed stereosubstitution (GPS) to create relevant selectin-binding glycan determinants on the cell surface . We report here that GPS enforces expression of E-selectin ligands on NSCs by modifying glycans of two NSC membrane glycoproteins, CD44 and of neural cell adhesion molecule (NCAM), creating the E-selectin ligands HCELL (hematopoietic cell E-/L-selectin ligand) and E-selectin-binding glycoform of NCAM (NCAM-E), respectively. Glycoengineering of NSC E-selectin ligand activity resulted in increased neurotropism and yielded improved clinical outcome in EAE in the absence of detectable long-term engraftment, indicating that these tissue-specific stem cells engendered a repair effect, not a direct cell replacement effect. Importantly, this beneficial effect is not a universal property of adult stem cells, as administration of GPS-engineered mouse hematopoietic stem/progenitor cells (HSPCs) did not improve EAE clinical course. These findings have profound clinical implications in providing the first direct evidence that cell surface glycoengineering to create effectors of cell migration can improve the efficacy of stem cell-based therapeutics and also provide new perspectives on the use of NSCs in the treatment of neuroinflammatory diseases.
Results

Expression of molecular effectors of cell migration on neural stem cells
To analyze expression of molecular effectors of Steps 1, 2 and 3/4 of cell migration, flow cytometry was performed on primary cultures of mouse NSCs. NSCs were devoid of reactivity with E-selectin-Ig chimera (E-Ig) and P-selectin-Ig chimera (P-Ig), indicating the absence of E-and P-selectin ligands ( Figure 1A ) even in the presence of inflammatory mediators (Supplementary data, Figure S1 ); they also did not stain with mAb CSLEX1, KM93 or HECA452 (each of which identify sLe x ). NSCs expressed CD44 and the integrins VLA-4 (CD49d/CD29) and VLA-5 (CD49e/CD29), as well as the chemokine receptor CXCR4; this pattern of NSC marker expression has been observed by others (Pluchino et al. 2003 (Pluchino et al. , 2005 Campos et al. 2004 Campos et al. , 2006 Imitola, Raddassi, et al. 2004; Ji et al. 2004; Back et al. 2005; Leone et al. 2005 ) ( Figure 1B ). The NSCs also characteristically expressed NCAM in addition to the well-described polysialic acid (PSA) (Vitry et al. 2001 ) ( Figure 1B ). NSCs did not express PSGL-1, CD43, LFA-1 [lacking both CD11a (α 1 ) and CD18 (β 2 ) chains] and LPAM-1 (α 4 β 7 ) ( Figure 1B ). These results indicate that NSCs are defiNeural stem cell glycoengineering optimizes neurotropism cient in expression of Step 1 effectors of the multistep cascade of cell transmigration, yet express chemokine receptors and relevant integrin effectors that mediate Steps 2-4 in extravasation and that are also involved in their mobilization in the developing brain via radial migration (Imitola, Comabella, et al. 2004 ).
GPS enforces E-selectin ligand activity on neural stem cells CD44, a molecule involved in migration of NSCs (Deboux et al. 2013 ) and brain cancer stem cells (Fu et al. 2013) , is strongly expressed among NSCs in culture ( Figure 1B) . However, the finding that NSC lacks E-selectin binding ( Figure 1A ) indicates that these cells do not natively express the E-selectin-binding glycoform of CD44 known as HCELL (Dimitroff et al. 2000 (Dimitroff et al. , 2001 Sackstein 2004) . We thus sought to determine whether a nongenetic manipulation using GPS of CD44 glycans would enforce HCELL expression . To this end, we treated NSCs with the α(1,3)-linkage-specific fucosyltransferase, fucosyltransferase VI (FTVI). This enzyme specifically places a fucose onto a terminal type 2-lactosamine unit; if that lactosamine is capped with an α(2,3)-linked sialic acid, sLe x is created.
Following FTVI treatment of NSCs (GPS-NSC), reactivity with mAbs CSLEX1, KM93 and HECA452 was induced, consistent with strong expression of sLe x epitopes ( Figure 2A ), with associated E-Ig binding ( Figure 2A ) but without induction of P-Ig binding ( Figure 2A) . Notably, expression of CD15 (also known as SSEA-1 or Le x ) is high in NSCs (Figure 2A) , and although FTVI can fucosylate unsialylated terminal lactosamines thereby yielding CD15 (SSEA-1), the expression of CD15 was unchanged following enforced fucosylation ( Figure 2A ). As determined by microarray analysis of murine NSCs, the fucosyltransferases involved in creating these Le x (CD15) structures on NSCs may be attributed to FTIX, FTX and FTXI (Supplementary data, Figure S2 ). Recent studies have implicated that FTX is involved in α-1,3-fucosyltransferase activity with strict substrate specificity (adding fucose to GlcNAc at the innermost core position of N-glycans and/ or on bisecting N-glycans of glycoproteins) (Mollicone et al. 2009; Kumar et al. 2013) synthesizing Le x only on restricted glycoprotein substrates that may not be common to the sialylated lactosamine structures recognized by other fucosyltransferases such as the FTVI. Altogether, these data indicate that α(1,3)-exofucosylation only occurred on sialylated lactosaminyl glycans. Bromelain digestion of NSCs prior to GPS treatment markedly reduced HECA452 reactivity NSCs lack E-selectin ligands but express a number of other cell surface adhesion molecules. (A) Flow cytometric analysis of HECA452, KM93, CSLEX-1, E-selectin ligand (E-Ig binding) and P-selectin ligand (P-Ig binding) expression on NSCs. The corresponding isotype controls showed overlapping signals for each antibody surveyed, i.e., rat IgM (for HECA-452; MFI: 1.9), mouse IgM (for KM93 and CSLEX-1; MFI: 2.7) and human IgG 1 (for E-Ig and P-Ig; MFI: 3.5).
A histogram plot representing a typical E-Ig binding profile illustrates that over 99% of the cells consistently express E-Ig binding following GPS. (B) Flow cytometric analysis of CD43 (S7 and 1B11), PSGL-1 (2PH1, 4RA10), CD44 (IM7, KM114), NCAM (CD56), PSA, CD49d, CD49e, CD29, LPAM-1, CD11a, CD18 and CXCR4. The dotted line is isotype control, and the black line is specific antibody. All results displayed are representative of n = 5 flow cytometry experiments performed on NSCs.
( Figure 2B ), demonstrating that glycoproteins, not glycolipids, were the predominant carriers of sialofucosylated determinants. Treatment of GPS-NSCs with phosphatidylinositol phospholipase C (PI-PLC) resulted in a modest but significant decrease in the HECA452 signal by flow cytometric analysis ( Figure 2C ), indicating that a minor population of sLe x -decorated glycoproteins are glycophosphatidyl inositol (GPI)-linked. Western blot of cell lysates and of immunoprecipitated CD44 from GPS-NSCs revealed that one of the glycoproteins decorated with the essential sialofucosylations recognized by HECA452 was the standard, unspliced form of CD44 (∼100 kDa; Figure 3A) , and CD44 also reacted with E-Ig ( Figure 3A) . However, following immunoprecipitation of CD44, other candidate glycoprotein E-selectin ligand(s) were identified by evidence of reactivity with E-Ig and HECA452 in the residual supernatant (SN) fraction. Two bands were apparent at ∼120 and ∼140 kDa. Based on the molecular weight profile of these bands ( Figure 3A ) and the partial PI-PLC sensitivity of E-selectin binding ( Figure 2C ), a characteristic of the 120 kDa form of NCAM (Gascon et al. 2007; Maness and Schachner 2007; Rutishauser 2008) , we speculated that NCAM could be serving as an additional E-selectin ligand. We thus performed immunoprecipitation with a pan-NCAM mAb and observed that the residual bands persisting after immunoprecipitation of CD44 were indeed those of NCAM ( Figure 3B ). In addition, following immunoprecipitation of CD44 and exhaustive immunoprecipitation of NCAM, only a very anemic E-selectin signal was observed indicating that CD44 and NCAM were the major E-selectin ligands present after GPS treatment of NSCs (Supplementary data, Figure S3 ). To determine if the relevant sialofucosylations on NCAM were displayed on N-glycans, we tested E-Ig reactivity on western blot of lysates of GPS-NSCs following digestion with N-glycosidase F (PNGaseF) ( Figure 3B ); no evident staining with E-Ig following digestion was observed, indicating that the relevant E-selectin binding determinant(s) are displayed on N-glycans. The contribution of the GPI-anchored form of NCAM-E to overall sLe x expression after enforced fucosylation of NSC is modest, as shown by a small decrease in HECA452 signal (and E-Ig signal-data not shown) following PI-PLC treatment (Figure 2C) . Therefore, enforced α(1,3)-fucosylation of murine NSCs created HCELL as well as a unique E-selectin ligand reactive form of the neural precursor molecule NCAM, which we named "NCAM-E". Interestingly, human NSCs (CC-2599) only express HCELL and not NCAM-E following GPS treatment (Supplementary data, Figure S4 ). To assess the stability of GPS-engineered E-selectin ligand activity on NSCs, we measured E-Ig reactivity by flow cytometry at 24 h intervals following enforced exofucosylation. E-selectin ligand activity was stable for up to 24 h, subsequently declining to undetectable levels by 72 h, presumably due to turnover of surface protein ( Figure 3C ). NSC viability (Supplementary data, Figure S5 ) was unaffected by enforced exofucosylation, and there were no differences in the number or proliferation of neurospheres in clonogenic assays or in differentiation of NSCs (Supplementary data, Figure S6 ). Thus, there were no evident phenotypic differences induced by GPS treatment of NSCs, except for creation of E-selectin ligands.
NSCs have been shown to inhibit the proliferation T cells in vitro (Einstein et al. 2006 (Einstein et al. , 2007 Martino and Pluchino 2006) , and, in particular, to dampen mitogenic responses of T cells in vitro. To assess whether this immunoregulatory function of NSCs is affected by enforced E-selectin ligand activity, we examined the ability of GPS-NSCs and control buffer-treated NSCs (BT-NSCs) to suppress the proliferation of lymph node cells in response to Con A activation. As displayed in Supplementary data, Figure S7 , both GPS-and BT-NSCs were able to decrease T cell proliferation as well as suppress the level of inflammatory cytokine production equally, suggesting that there is no immunomodulatory advantage or disadvantage provided by the GPS treatment itself on NSCs. Interestingly, we also observed equal release of leukemia inhibitory factor (LIF) from NSCs upon inflammatory cytokine treatment for both BT-and GPS-NSCs that was enhanced upon binding of GPS-treated cells to E-Ig (Supplementary data, Figure S7C ). Thus, enforced exofucosylation of NSCs induced transient E-selectin ligand activity without undesirable effects on NSC phenotype or function as determined by in vitro studies.
GPS-NSCs display robust physiological rolling interactions with E-selectin
To analyze the potency of E-selectin ligand activity of GPS-NSCs under physiologic blood flow conditions, parallel plate flow chamber studies were performed using human umbilical vein endothelial cells (HUVECs) stimulated by cytokines (IL-1β and TNF-α) to express E-selectin. As shown in Figure 4A , GPS-NSCs exhibited prominent E-selectin ligand activity that was completely abrogated in the presence of ethylenediaminetetraacetic acid (EDTA) or by the use of a blocking anti-E-selectin mAb. Significant shear-resistant rolling interactions were observed within usual post-capillary venular shear levels (1-4 dynes/cm 2 ) and persisted over 20 dynes/cm 2 ( Figure 4A ). To analyze which of the glycan-engineered E-selectin ligands, HCELL or NCAM-E, is the more potent E-selectin ligand on NSCs, we used the blot-rolling assay (Fuhlbrigge et al. 2002) . This technique permits the detection of shear-dependent selectin ligand interactions on membrane proteins resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), thus allowing the evaluation of the individual contribution of HCELL and NCAM-E to the E-selectin ligand activity of GPS-NSC. Accordingly, to evaluate the respective E-selectin binding properties, E-selectin-transfected CHO cells (CHO-E) were perfused over HECA-452-immunostained blots of GPS-NSC lysates.
As illustrated in Figure 4B , more CHO-E cells interacted and adhered to HCELL compared with either the 120 kD or the 140 kD forms of NCAM-E. CHO-E cells suspended in flow medium containing 5 mM EDTA had negligible adhesion to any regions of the blot, confirming Ca 2+ -dependent binding consistent with selectin ligand activity.
GPS-NSCs exhibit increased homing and tissue infiltration in vivo in EAE
To assess whether injected NSCs infiltrated the CNS parenchyma, we performed confocal microscopy studies. To this end, GPS-NSCs and BT-NSCs were labeled with PKH26 dye and were injected intravenously (i.v.) into myelin oligodendrocyte glycoprotein (MOG)-induced chronic EAE mice in two separate i.v. injections: before disease onset [Day 9 post-immunization (PI)] and at the onset of the disease (Day 13 PI). These days were chosen based on prior studies of E-selectin expression on brain endothelium in EAE (Piccio et al. 2002) . Lumbarsacral spinal cords and brains were harvested 4 days (Day 17 PI) after the second NSC injection. Confocal analysis of the brain demonstrated both higher amounts of GPS-NSCs ( Figure 5A ) and localization outside of Flk-1 + vessels in the brain (Supplementary data, Figure S8 ). Further, parallel analysis of the spinal cord ( Figure 5B -D), where the majority of pathology occurs in EAE, demonstrated 2-fold greater numbers of extravascular GPS-NSCs infiltrates over BT-NSCs infiltrates by Day 17 PI ( Figure 5D ). These data indicate that GPS-NSCs infiltrate the CNS parenchyma significantly more effectively than BT-NSCs in both the brain and the spinal cord. To further confirm our confocal data, we studied the effect of GPS-engineered E-selectin ligand activity on short-term homing of NSCs in vivo. Syngeneic NSCs were stained using a fluorochrome tracking dye, carboxyfluorescein diacetate succinimidyl ester (CFDA-SE), and adoptively transferred into C57BL/6 mice on Days 9 and 13 PI with MOG as described in the Materials and methods section. Within 16 h after the second cell injection, we observed that GPS-NSCs accumulated in the brain, spleen and liver 3-to 5-fold more efficiently than BT-NSCs ( Figure 5E ). The relative advantage of GPS-NSCs in infiltrating the brain, spleen and liver reflected a true difference in trafficking and not simply the preferential expansion of these cells in situ, as their average CFDA-SE fluorescence was not reduced relative to BT-NSCs (data not shown). Indeed of those cells that migrated to the spleen, it is evident that there are close interactions of NSCs with CD4 + T cells ( Figure 5F ). Injected cells also accumulated in the lungs, but without difference between GPS-and BT-NSCs, likely a reflection of steric trapping in pulmonary microvessels ( Figure 5E ). Thus, the sLe x structure formed on NSCs following GPS treatment licenses migration of these cells into these organs and highlights the critical role of the E-selectin ligand activity in driving tissue-specific migration of NSCs in vivo.
GPS-NSCs increased homing translates into amelioration of neuropathology by enhanced endogenous indirect neuroregeneration in EAE
To address whether improved tissue homing of NSC had an enhanced therapeutic effect, we monitored the neurologic status of C57BL/6 mice receiving NSC injections following MOG-induced chronic EAE and analyzed clinical parameters as well as tissue repair and pathology. Neural precursors were administered in two separate i.-v. injections on Days 9 and 13 PI. Five groups of EAE mice were tested:
(1) GPS-NSCs, (2) BT-NSCs, (3) hank's balanced salt solution (HBSS) (sham; i.e., no cells), (4) BT-HSPC and (5) GPS-HSPC. The clinical score was evaluated daily in individual mice in a blind fashion ( Figure 6A ), and the linear regression of cumulative burden of disease was calculated ( Figure 6B and Table I ). The injection of control NSCs (BT-NSC) attenuated the clinical severity of EAE compared with HSPC-and sham-treated animals (P = 0.006). However, i.v. injection of GPS-NSCs (n = 30) showed a more significantly improved clinical score compared with BT-NSCs (n = 30; P = 0.006), GPS-HSPC (n = 30; P < 0.0001), BT-HSPC (n = 30; P < 0.0001) and sham (n = 30; P < 0.0001) treated animals. It is important to note that this amelioration of disease severity is specific to NSCs, since neither the injection of GPS-HSPC [which display markedly increased E-selectin ligand activity, see Supplementary data, Figure S9A (Merzaban et al. 2011)] or the injection of BT-HSPC showed an improvement in the clinical score of MOG-induced animals compared with control animals (Supplementary data, Figure S9B , C and Table S1 ). Indeed, injection of either GPS-or BT-HSPCs showed a trend toward worsened clinical outcomes indicating that the observed salutary effects of NSC infusion are not a general property of adult stem cells. Notably, examination of the neuropathology at Day 30 after EAE induction showed statistically significant differences in several parameters of inflammation and neuroregeneration in mice that received GPS-NSC compared with BT-NSC-and sham-treated animals ( Figure 6C ). To determine the impact of NSC injections on the neuropathology of EAE, we evaluated a number of different markers. First, to assess the extent of inflammation, we stained sections of spinal cord from each study group of mice for CD11b, a marker that identifies infiltrating macrophages and microglia. Animals with EAE that received HBSS buffer alone displayed high levels of staining for CD11b, with cells exhibiting increased numbers of membrane processes, morphologic evidence of an activated phenotype ( Figure 6C ). The numbers of CD11b-stained cells were significantly decreased in mice that received BT-NSCs (P < 0.0001), and notably, these levels were even further decreased in animals injected with GPS-NSCs (P < 0.005 compared with BT-NSCs). Importantly, the macrophage/microglia displayed decreased CD11b staining and more discrete membrane processes indicative of decreased activation ( Figure 6C ). In addition, quantification of brain CD4 + T cells in the different treatment groups revealed a significant decrease of infiltrating T cells in animals given GPS-NSCs ( Figure 6D and E). To assess neuroregeneration, we stained sections of spinal cord for the markers GAP-43 and SMI-32 ( Figure 6F-I) . In animals injected with GPS-NSCs, there was increased expression of GAP-43, a molecule associated with axon integrity and regeneration, compared with that in mice that received either BT-NSCs or HBSS buffer alone ( Figure 6F -G). Conversely, a specific reduction in the expression of SMI-32, a marker of axonal degeneration, was observed in animals that received GPS-NSCs compared with mice receiving either BT-NSCs or HBSS buffer ( Figure 6H and I). These data support the notion that the improved clinical effects afforded by GPS-NSCs over BT-NSCs are secondary to increased lesional migration of tissue-specific NSC yielding enhanced neuroprotection. To further assess whether observed effects of GPS-NSCs reflect increased neuroregeneration, we stained for markers associated with oligodendrogenesis and mature oligodendrocytes, including CNPase, Olig-2 and SOX9. We observed a statistically significant enhancement in the number of Olig-2, SOX9 and CNPase cells in animals that received GPS-NSCs compared with BT-NSCs or sham control ( Figure 6D and E). Although there was evidence of injected NSCs at Day 17 PI (SOX-2 + cells; Supplementary data, Figure S8 ), we did not observe persistent colonization by NSC (tagged with GFP) at 30 days PI (Supplementary data, Figure S10 ) in any of the injection groups, suggesting that the mechanism of NSC neuroprotection associated with improved homing does not necessitate the continued presence nor differentiation toward neural lineage cells, of administered NSCs. Altogether, these data indicate that the treatment of mice with GPS-NSCs enhanced the delivery of NSCs to the CNS, resulting in improved endogenous tissue regeneration.
Discussion
EAE is a model of a chronic, demyelinating disease of the CNS characterized by multifocal inflammatory lesions yielding gradual destruction of the myelin sheath, leading to axonal injury and loss (Imitola et al. 2006 ). Stem cell-based therapeutics offers the promise of repair of damaged/inflamed tissue by replacing affected cells (direct regeneration) and/or by production of supportive/trophic factors in the milieu that evoke tissue regeneration by endogenous cells (indirect regeneration). In the case of disseminated neurologic diseases like MS, use of tissue-specific NSCs could prove clinically useful in achieving CNS recovery, but a proximate hurdle to accomplishing this goal is to deliver adequate numbers of cells to the sites of neural injury.
Prior studies have shown a benefit of transplanted NSCs in experimental models of stroke, spinal cord trauma and MS (Ben-Hur et al. 2003; Pluchino et al. 2003 Pluchino et al. , 2005 Imitola, Raddassi, et al. 2004; Einstein et al. 2006 Einstein et al. , 2007 Ziv et al. 2006; Lee et al. 2008) . Direct injection into the affected site was used as route of delivery in these studies; however, in order to attain appropriate colonization of NSC within affected tissue(s) in multifocal CNS diseases, the vascular route of delivery is required as local administration (i.e., in situ injection) is impractical given the diffuse nature of disease and associated anatomic constraints. To date, there have been no studies to evaluate the expression of molecular effectors of cell migration on NSCs, and, more importantly, no studies to address how optimizing expression of such effectors could enhance NSC neurotropism. Our studies reveal that NSCs express relevant Step 2-4 effectors, but are conspicuously deficient in Step 1 effectors: (1) they do not natively express ligands for E-selectin or P-selectin [even when grown in the presence of inflammatory cytokines (Supplementary data, Figure S1 )]; (2) they lack expression of the glycan sLe x , which is the canonical selectin binding determinant and (3) they do not express the glycoprotein PSGL-1, a selectin ligand on myelin-specific Th1 cells that has been reported to mediate trafficking to the brain (Piccio et al. 2002 (Piccio et al. , 2005 . Importantly, expression of endothelial selectins, especially E-selectin, has been implicated in recruitment of immunologic effectors in MS and EAE (Lee and Benveniste 1999; Piccio et al. 2002) . Thus, we sought here to assess whether glycan engineering of NSC to enforce expression of E-selectin ligands would enhance systemic delivery of the cells and, in consequence, have biologic effects in EAE. The dataset here shows that cultured NSCs express two wellcharacterized neural cell surface molecules, CD44 and NCAM (Pluchino et al. 2003; Back et al. 2005) . Strikingly, exofucosylation of mouse NSCs yielded high expression of sLe x determinants prominently on these glycoproteins, programming conversion of CD44 into the potent E-selectin ligand HCELL (Dimitroff et al. 2000 (Dimitroff et al. , 2001 and also inducing expression of two sialofucosylated glycoforms of NCAM of ∼120 and ∼140 kDa, which we designate "NCAM-E". Blot-rolling assays revealed that HCELL is the principal E-selectin ligand expressed on GPS-NSCs ( Figure 4B ). These findings are corroborated by results of flow cytometry following the removal of NCAM-E by PI-PLC digestion, showing considerable retention of NSC sLe x expression and E-Ig reactivity ( Figure 2C ). NCAM, a member of the immunoglobulin superfamily, is expressed on both neurons and glia and is conventionally viewed as a mediator of cell-cell interactions establishing a physical anchorage of cells to their environment. Posttranslational glycan modifications consisting of α-2,8-linked PSA on the NCAM protein core provide unique properties in neural migration (Gascon et al. 2007; Maness and Schachner 2007; Rutishauser 2008) , and PSA-NCAM appears to play a crucial role in mediating precursor cell migration in the brain (Zhang et al. 2004; Lavdas et al. 2006; Glaser et al. 2007) . Our data now provide the first evidence that NCAM displays relevant terminal α-(2,3)-sialyllactosaminyl glycans that can serve as acceptors for exofucosylation to create sLe x determinants. Following cell surface glycoengineering of NSCs, PSA expression levels did not change and the induced E-selectin ligand activity is not permanent, as there was complete loss of sLe x expression within 72 h of enforced fucosylation (Figure 3) . Thus, subsequent to extravasation, temporal reversion to native NCAM should occur, and infiltrating NSCs would then be capable of undergoing endogenous NCAM-mediated intraparenchymal CNS migration. Notably, though murine NSCs express NCAM bearing α-(2,3)-sialyllactosaminyl glycans, our studies of human NSCs (CC-2599) indicate that these cells only express HCELL and not NCAM-E following exofucosylation (Supplementary data, Figure S4 ); thus, human NSC may express relevant sialolactosaminyl glycans that serve as acceptors for enforced fucosylation only on CD44. These species differences should be considered when interpreting xenograft studies where human NSCs are used in rodent systems (Goncharova et al. 2014) .
The induction of E-selectin ligand activity has profound implications for cell trafficking, serving to direct cell migration to endothelial beds that express E-selectin. As shown by others, we observed that NSCs display the chemokine receptor CXCR4 and the integrin VLA-4 (see Figure 1) . It has been shown that expression of CXCR4 on human NSCs (Flax et al. 1998; Bezzi et al. 2001; Imitola, Raddassi, et al. 2004 ) promotes migration in vivo toward CNS injury wherein local astrocytes and endothelium upregulate the cognate ligand stromal cell-derived factor 1α (SDF-1α, also known as CXCL12) (Imitola, Raddassi, et al. 2004 ). These observations define CXCR4 as a prominent Step 2 effector in promoting NSC homing to CNS injury. The corresponding endothelial receptor for VLA-4, VCAM-1, is also upregulated in the inflammatory response of the brain to injury (Justicia et al. 2006) . The VLA-4/VCAM-1 axis has similarly been shown to play a critical role in migration of NSCs, in that only NSCs that constitutively express VLA-4, in addition to CXCR4, were able to accumulate around inflamed CNS microvessels in affected lesions in EAE (Pluchino et al. 2005) . A recent xenograft study suggests that integrins may play a role as Step 1 mediators of migration on human NSCs in a rat stroke model suggesting that selectin interactions are not necessary in this model system (Goncharova et al. 2014) . Although further work is warranted, the varying role(s) of integrins as mediators of Step 1 interactions could reflect differences in the inflammatory model used, the host animal system, the permeability of vessels, the expression of endothelial adhesion molecules at that site of inflammation, the presence of soluble adhesion molecules at the site and the physical properties of the vessel that dictate the flow rate (i.e., diameter of vessel) (Berlin et al. 1995; Ding et al. 1999; Zarbock et al. 2007 Zarbock et al. , 2012 . In any case, expression of E-selectin ligands as Step 1 effectors on NSCs would serve to complement the constitutive expression of CXCR4 and VLA-4, thereby optimizing the recruitment of NSCs to inflammatory sites. Accordingly, though we observed that intravenously administered (non-modified) BT-NSCs can infiltrate the brain of EAE mice ( Figure 5E ), enforced E-selectin ligand expression by glycoengineering (as determined by above in vitro assays) yielded markedly increased migration of NSCs to the brain. This increased neurotropism was associated with markedly diminished CNS inflammation (Figure 6) . Moreover, as shown in Figure 5 , NSC accumulation in the CNS parenchyma was 2-fold higher among GPS-NSCs than BT-NSCs by Day 17 PI, indicating that enforced expression of Step 1 effectors promotes extravasation.
In addition to enhanced neurotropism, short-term homing data also revealed a significantly higher accumulation of GPS-NSCs in the spleen and the liver than in BT-NSCs ( Figure 5E ). These findings are consistent with results of a study reporting that systemically administered NSCs tend to accumulate in the brains of mice with EAE, and also in the spleen and the liver (Politi et al. 2007 ). E-selectin expression in the spleen has been described in humans, non-human primates and rodents (Redl et al. 1991; Drake et al. 1993; Schweitzer et al. 1996; Alam et al. 2000) , and is upregulated by pro-inflammatory cytokines that are characteristically expressed in CNS inflammatory conditions (Weishaupt et al. 2000; Emamgholipour et al. 2013 ); indeed, conjugation of sLe x to polymers has been shown to markedly enhance the accumulation of such polymers within the spleen (Horie et al. 2000 (Horie et al. , 2004 , providing direct evidence that sLe x expression promotes splenic delivery. It has been reported that infiltration of the spleen by NSCs dampens production of inflammatory cytokines by resident spleen cells (e.g., macrophages) resulting in anti-inflammatory effects (Lee et al. 2008) . Other studies have reported that intravascularly administered NSCs provide peripheral immunosuppression (Einstein et al. 2006 (Einstein et al. , 2007 or local immunomodulation that restrains CNS injury, rather than by enhancing neuroregeneration Pluchino et al. 2009; Wang et al. 2009 ). Thus, the observed increased splenic homing by enforced expression of E-selectin ligand activity on NSCs could be contributory to neuroprotection via immunomodulation by virtue of increased tissue ratio of NSCs to immune cells. This notion is supported by our in vitro data showing that although GPS-NSCs did not confer an immunomodulatory advantage compared with that observed with control NSCs, as the ratio of input NSCs to splenocytes is increased, T cell proliferation decreases (Supplementary data, Figure S7A ). Previous studies of cell surface exoglycosylation had utilized human mesenchymal stem cells in a xenotransplant model and did not address the therapeutic impact on tissue injury, i.e., whether glycoengineered stem cells would home to a site of inflammation and whether such cells would have desired regenerative and/or tissueprotective effect(s). Though enhanced recruitment of NSCs to the CNS was observed following infusion of GPS-NSCs, there was no commensurate increase in long-term engraftment of NSCs. Thus, though enhanced CNS infiltration was achieved by exploiting physiologic cell migration (i.e., in a noninvasive fashion that would preserve CNS tissue microenvironmental architecture), we did not observe that administered NSCs differentiated into progeny that regenerate functional CNS tissue in situ (i.e., through direct regeneration). In fact, we observed that administration of GPS-NSCs improved the ability of endogenous neuronal progenitors to become oligodendroglia ( Figure 6D and E) as suggested by the increase in CNPase staining, a marker of mature oligodendrocytes. In order to correlate with differentiation in vivo, we quantified the expression of Sox-9 and Olig-2, two independent transcription factors associated with oligodendrogenesis that are expressed in oligodendrocyte precursors. Taken together, our results suggest that NSC infiltrates support oligodendrogenesis. However, our findings do not provide evidence for NSC-based direct neuroregeneration but instead suggest that the predominant role of NSCs in CNS tissue repair is via trophic effects that prime repair by endogenous cells (Phinney and Prockop 2007; Hess and Borlongan 2008; Caplan 2009; Laterza et al. 2013 ). Consistent with this notion, undifferentiated NSCs have been reported to significantly reduce scar formation and increase survival and function of endogenous glial and neuronal progenitors through the secretion of neurotrophins such as LIF (Laterza et al. 2013 ). In addition, NSCs support the formation of injury-induced growth niches through the expression of molecules such as BMP-4 and Noggin (Imitola, Raddassi, et al. 2004; Pluchino et al. 2005 ) that trigger indirect neuroregeneration by endogenous cells.
Collectively, our data support a mechanism in which glycan engineering of NSC to enforce expression of E-selectin ligands heightens tissue colonization, mediating immunomodulation and tissue repair without necessitating persistent/long-term engraftment of administered NSCs. Notably, despite enhanced E-selectin ligand activity, infusion of GPS-HSPC did not improve the course of EAE (indeed, injection of HSPC worsens disease, see Supplementary data, Figure S9 and Table S1 ), indicating that the observed neuroprotective effects of GPS-NSCs are not a general property of adult stem cells and are due to intrinsic factors related to NSCs. Consistent with this finding of adult stem cell-specific biologic effect(s), human HSPCs have been found to elicit strong host immune rejection in a mouse model of congenital corneal disease, while other adult stem cells such as mesenchymal stem cells suppress the host immune response (Liu et al. 2010 ). Though further studies on the molecular mechanism(s) mediating the observed neuroprotection by NSCs are warranted, our results indicate that cell surface glycan engineering did not change the self-renewal capacity, differentiation potential or alter the innate immunomodulatory capacity of NSCs. Collectively, the data presented here lead us to propose a model (Supplementary data, Figure S11 ) whereby enforced E-selectin ligand expression via exofucosylation of the surface of NSCs yields increased tissue recruitment at CNS inflammatory sites, thereby enhancing payload delivery of NSC trophic factors where they are needed. Because E-selectin expression is markedly upregulated at endothelial beds at all sites of inflammation in humans, our findings have profound translational implications for future clinical trials exploiting cell surface glycan engineering to improve the efficacy of stem cell therapeutics for MS as well as other devastating multifocal inflammatory diseases.
Materials and methods
Ethics statement
All mouse experiments were performed in accordance with the National Institutes of Health guidelines for the care and use of animals and under approval of the Institutional Animal Care and Use Committees of Harvard Medical School. The following are the specifics related to using mice in these experiments. Justification for use: EAE is a valuable model for the human disease MS. There are no mathematical models, computer simulations or in vitro systems that can substitute for the in vivo disease. Many of the treatments available for MS and other autoimmune diseases were first tested and their mechanisms investigated in EAE. MOG-induced EAE in C57/BL6 mice is valuable because of the availability of many knockout and transgenic mice on that background. Veterinary care: Mice are handled and cared for according to federal, institutional and association for assessment and accreditation of laboratory animal care guidelines. Procedures to minimize adverse effects: After immunization, animals are examined daily. Those affected by EAE develop a floppy tail (Grade 1), partial hind limb paralysis (Grade 2), complete hind limb paralysis (Grade 3), quadriparesis (Grade 4), moribund or animal death (Grade 5). Most animals have a Grade 0-3, and, rarely, animals reach Grade 4, and in such cases, euthanasia is performed. When animals are affected by EAE, they are provided with gel packs to ensure access to fluids and are provided with access to food within the cage. Euthanasia is performed by CO 2 inhalation administered according to institutional guidelines.
Reagents
The following antibodies were purchased from BD Pharmingen (MA, USA): function-blocking mouse anti-human E-selectin (68-5H11; IgG1), rat anti-human cutaneous lymphocyte antigen (CLA) (HECA-452; IgM), mouse anti-human sLe x (CSLEX-1; IgM), mouse anti-human CD15 (IgM), rat anti-mouse PSGL-1 (2PH1 and 4RA10; IgG1), mouse anti-human PSGL-1 (KPL-1; IgG1), rat anti-mouse CD44 (KM114 and IM7; IgG1), mouse anti-human CD44 (515; IgG1), rat anti-mouse CD43 (S7; IgG2a), mouse anti-human CD43 (1G10; IgG1), mouse anti-(mouse anti-adult and embryonic pan N-Cam) CD56 (NCAM13; IgG2b), mouse anti-human CD56 (NCAM16.2; IgG2b), rat anti-human CXCR4 (2B11; IgG2b), mouse anti-human CXCR4 (12G5; IgG2a), rat anti-mouse CD18 (GAME-46; IgG1), rat anti-mouse CD29 (KM16; IgG2a), rat antimouse CD49d (9C10; IgG2b), rat anti-mouse CD11a (2D7; IgG2a), rat anti-mouse CD11b (M1/70; IgG2b), rat anti- 
Cells
Mouse NSCs were isolated and cultured as described previously (Imitola, Comabella, et al. 2004; Imitola, Raddassi, et al. 2004 ). Briefly, a suspension of dissociated NSCs (5 × 10 5 cells per mL), isolated from the telencephalic VZ of embryonic day 12, was cultured in 98% Dulbecco's modified Eagle's medium (DMEM)/F12 (GIBCO), 1% N 2 supplement (GIBCO), 1% penicillin/streptomycin (GIBCO), 8 mg/mL heparin (Sigma), 10 ng/mL leukemia inhibitory factor (LIF, Chemicon), 20 ng/mL bFGF (Calbiochem) in uncoated 25 cm 2 flasks (Falcon) at 37°C in 5% CO 2 . NSCs were used after second passage for most experiments. Single-cell suspension of NSCs was achieved by mechanical dissociation of the neurospheres in Versene (Life Technologies). For isolation of mouse HSPC, bone marrow was harvested from the femur and tibia of C57BL/6 mice and single-cell suspensions were made. Red blood cells were lysed using red blood cell lysing buffer (Sigma; MO, USA). Cells were then washed and filtered through a 100 μm cell strainer (BD Falcon) prior to lineage depletion using the Lineage Cell Depletion Kit from Miltenyi Biotec (MA, USA). Cell preparations were depleted using the autoMACS™ Separator (Miltenyi Biotec.). Following depletion, the cells were then positively selected for c-kit using CD117 MicroBeads (Miltenyi Biotec.). The resulting Lineage neg C-kit pos population (referred to as HSPC) was used for in vivo EAE mouse studies.
Chinese hamster ovary cells transfected with full-length E-selectin (CHO-E) and were maintained as described previously (Dimitroff et al. 2001 ). The human βFGF-dependent NSC cell line, CC-2599, was cultured as previously described (Imitola, Raddassi, et al. 2004 ) and used for data presented in Supplementary data, Figure S4 . The cumulative burden of disease was assessed by performing a linear regression analysis comparing the slope of the curves in (A). These data highlight GPS-NSCs (green dotted line) significantly improve the clinical scores above that of BT-NSCs (red line). Mice receiving either GPS-NSCs or BT-NSCs displayed significantly improved clinical scores compared with mice that did not receive NSCs (No NSCs; black line). These data also suggest that BT-HSPCs (blue line) and GPS-HSPCs ( purple line) worsen disease. (C) Neuropathology at Day 30 PI of the brain from EAE mice injected with NSCs was analyzed by staining with anti-CD11b mAb (green) and the nuclear label To-Pro3 (blue). GPS-NSC injection leads to significantly less injury per brain section as measured by numeration of CD11b macrophage/microglia from 20 different sections of 3 different spinal cords. Bar graphs depict the numeration of CD11b macrophage/ microglia in spinal cord sections per HPF from EAE mice that received No NSC, BT-NSC or GPS-NSC and also the numeration of infiltrates per HPF were calculated based on To-Pro3 staining. White boxes correspond to higher-magnification images. Yellow arrowheads correspond to activated microglia, and white arrows correspond to infiltrates in the meninges (m). Note that the microglia in the No NSC samples are more activated than those found in the BT-NSC and GPS-NSC samples. Also the size of the infiltrates in the meninges is larger in the No NSC samples than in the BT-NSC samples. Scale bars, 100 μm for top panels. Scale bars, 50 μm for bottom panels. (D) Neuropathology of the brain from EAE mice injected with NSCs was analyzed by staining 20 different sections of 3 separate brains from mice that either received no NSCs (EAE No NSCs), BT-NSC (EAE BT-NSCs) or GPS-NSC (EAE GPS-NSCs) with CD4 (to measure T cell infiltrations), CNPase (to quantify mature oligodendrocytes), Olig-2 (to measure oligodendroglial differentiation) or SOX-9 (to measure multipotency of neural precursors) (green) and To-Pro3 (blue). GPS-NSC injection lead to significantly less T cell infiltrations, higher numbers of oligodendroglia and preservation of progenitor numbers. (E) Bar graphs depict the numeration of CD4 T, CNPase, Olig2 and SOX-9 cells in brain sections per HPF from EAE mice that received No NSC, BT-NSC or GPS-NSC (as outlined in D), indicating that animals that received GPS-NSCs display enhanced neuroprotection of progenitor cells. (F-I) GPS-NSC and BT-NSC injection leads to increased axonal regeneration and axonal protection compared with No NSC control as measured by increased GAP-43 (green; P < 0.001) staining (F) and by decreased staining with the monoclonal antibody SMI32 (red; P < 0.001) (H) as assessed by quantitative confocal imaging of GAP43 pixel intensity in >500 individual measurements. To-Pro3 staining dye was used to detect cell nuclei (blue). (G and H) Based on quantitative confocal imaging of >500 individual measurements of pixel intensity (Imitola et al. 2011) , graphical representation of GAP-43 (G) and SMI32 (I) was determined; note that SMI32 patterns (I) demonstrated axonal ovoids in animals with EAE, but reduction in animals injected with NSCs (I) and SMI32 pixel intensity showed a gradual correction of axonal integrity in animals with GPS-NSCs. There is a reduction of axonal ovoid and axonal fragments compared with controls and BT-NSCs as depicted in the cartoon below (I). Scale bar, 100 μm except for SMI32 staining where scale bar, 50 μm. No NSC -30 13.22 ± 0.6 2.2 ± 0.4 15.75 ± 0.6 14.9 ± 2.4 NSCs BT i.v. 30 12 ± 0.6 2.1 ± 0.3 12.3 ± 0.9 10.9 ± 2 NSCs-GPS i.v. 30 12.2 ± 0.5 1.8 ± 0.1 ns 10.8 ± 1.4 ns 7.1 ± 1.5* *P < 0.05 ANOVA multiple comparisons. PI; post immunization.
GPS treatment, PI-PLC and bromelain reactions
The procedure for GPS treatment of murine NSCs was as previously described for MSCs . Briefly, neurospheres were first harvested and dissociated into single cells by incubating with phosphate-buffered saline (PBS)/EDTA (0.02%) for 15 min at 37°C. Cells were then washed with HBSS, counted and resuspended in 60 mU/mL FTVI in HBSS (without Ca 2+ or Mg 2+ ) containing 20 mM N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES), 0.1% human serum albumin and 1 mM guanosine diphosphate-fucose for 40 min at 37°C. PI-PLC reactions were performed at 37°C using 0.1 U/mL for 1 h. Bromelain reactions were performed at 37°C in HBSS + 2% bovine serum albumin (BSA) + 0.1% bromelain for 1 h.
Flow cytometry
Aliquots of cells (2 × 10 5 cells) were washed with PBS/2% fetal bovine serum (FBS) and incubated with primary mAbs or with isotype control mAbs (either unconjugated or fluorochrome conjugated). The cells were washed in PBS/2% FBS and, for indirect immunofluorescence, incubated with appropriate secondary fluorochrome-conjugated anti-isotype antibodies. After washing cells, Fluorescein isothiocyanate or PE fluorescence intensity was determined using a Cytomics FC 500 MPL flow cytometer (Beckman Coulter, Inc., Fullerton, CA) or with a BD FACSCanto II cytometer (BD Biosciences, Germany).
Immunoprecipitation studies
Cell lysates of BT-NSC or GPS-NSC were incubated with immunoprecipitating antibodies or with appropriate isotype controls and then incubated with Protein G-agarose. Immunoprecipitates were washed extensively using Buffer A containing 2% NP-40 and 1% SDS. In some experiments, immunoprecipitates were treated with N-glycosidase F (New England Biolabs, MA, USA) as previously described (Dimitroff et al. 2001) . For western blot analysis, all immunoprecipitates were diluted in reducing sample buffer, boiled, then subjected to SDS-PAGE, transferred to PVDF membrane and immunostained with HECA-452 or E-Ig.
Western blot analysis
BT-and GPS-NSCs were lysed using 2% NP-40 in Buffer A [150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 20 μg/mL PMSF, 0.02% sodium azide and protease inhibitor cocktail tablet (Roche Molecular Biochemicals IN, USA)]. Western blots of quantified protein lysates or of immunoprecipitated protein were performed under reducing conditions as described previously (Dimitroff et al. 2001) . Blots were visualized with chemiluminescence using Lumi-Light Western Blotting Substrate (Roche).
Parallel plate flow chamber adhesion assays E-selectin binding capacity of BT-NSCs and GPS-NSCs was compared using the parallel plate flow chamber assay (Glycotech; Gaithersburg, MD). NSCs (0.5 × 10 6 cells/mL, suspended in HBSS/10 mM HEPES/ 2 mM CaCl 2 solution) were perfused over confluent HUVEC monolayers. Initially, the NSCs were allowed to contact the HUVEC monolayer at a shear stress of 0.5 dyne/cm 2 , subsequently the flow rate was adjusted to exert shear stress ranging from 0.5 to 30 dynes/cm 2 . The number of BT-or GPS-NSCs adherent to the HUVEC monolayer was quantified in the final 15 s interval at shear stress of 0.5, 1, 2, 5, 10, 20 and 30 dynes/cm 2 . Each assay was performed at least three times and the values averaged. Control assays were performed by adding 5 mM EDTA to the assay buffer to chelate Ca 2+ required for selectin binding or treating HUVEC with function-blocking antihuman E-selectin mAb at 37°C for 15 min, prior to use in adhesion assays.
Blot-rolling assay
The blot-rolling assay has been described previously (Dimitroff et al. 2000; Fuhlbrigge et al. 2002; Sackstein and Fuhlbrigge 2006) and here was used to detect selectin binding activity of NSC membrane proteins resolved by SDS-PAGE. Western blots of NSC membrane preparations were stained with anti-CLA (HECA-452) and rendered translucent by immersion in DMEM with 10% glycerol. CHO-E cells were resuspended (5 × 10 6 /mL) in DMEM containing 2 mM CaCl 2 and 10%
glycerol. The blots were placed under a parallel plate flow chamber, and CHO-E cells were perfused at a physiologically relevant shear stress of 1.0 dyne/cm 2 , an adjustment in the volumetric flow rate was made to account for the increase in viscosity due to the presence of 10% glycerol in the flow medium. Molecular weight markers were used as guides to aid placement of the flow chamber over stained bands of interest. The number of interacting cells per square millimeter was tabulated as a function of the molecular weight region and compiled into an adhesion histogram. Nonspecific adhesion was assessed by perfusing CHO-E cell suspensions containing 5 mM EDTA in the flow medium. 
Immunization for EAE induction and neural stem cells injection
Short-term homing studies
BT-NSCs and GPS-NSCs were labeled with 5 mM CFDA-SE (Invitrogen) for 5 min at room temperature in Roswell Park Memorial Institute (RPMI)-1640 containing 10% FBS and injected intravenously into MOG-treated C57BL6 mice on Days 9 and 13 PI. Two million NSCs in a volume of 0.2 mL of HBSS were injected into each mouse on each day. HBSS buffer alone was used to determine background signals. BT-NSCs and GPS-NSCs were also injected into animals that were not immunized with MOG and used to standardize the signals observed in each tissue assayed. Sixteen hours after the second NSC transfer, mice were sacrificed and perfused with 1× PBS without Ca 2+ and Mg
2+
. The brain, spinal cord, lymph nodes, spleen, liver and lung were isolated. The brain and the spinal cord were homogenized. Resulting pellets were resuspended in 0.25% Trypsin-EDTA (Invitrogen) and incubated at 37°C for 10 min. The digestion process was stopped using DMEM containing 0.01% SBTI, 0.001% DNase and 0.075% BSA. The lymph nodes, spleen and liver were mechanically dissociated and the resulting singlecell suspensions were assessed for frequencies of CFDA-SE positive cells by flow cytometry in the FL1 channel. Flow cytometric data was analyzed and expressed as percent of CFDA-SE-positive events detected in 200,000 cells scanned within a narrow gate that is set to include NSC. This gate was determined based on mixing cultured NSCs with suspensions of cells isolated from each tissue tested (brain, spinal cord, lymph node, spleen, liver and lung).
Analysis of NSC migration to CNS
BT-NSCs, GPS-NSCs were labeled with PKH26 dye (Invitrogen) and injected intravenously into MOG-treated C57BL6 mice on Days 9 and 13 PI. One million NSCs in a volume of 0.2 mL of HBSS were injected into each mouse on each day specified. HBSS buffer alone was used to determine background signals. Four days after the second NSC transfer, mice were sacrificed and perfused with 1× PBS without Ca 2+ and Mg 2+ and lumbar-sacral spinal cords were harvested. The spinal cord was chosen because in the B6 model, the CNS lesions in the forebrain are very variable in size and location compared with the spinal cords, which possess a more predictable location (lumbosacral region) and also more exuberant pathology (Chitnis et al. 2001; Rasmussen et al. 2007; Wang et al. 2008) . For flow cytometric analysis, the spinal cords were then homogenized and the resulting pellets were resuspended in 0.25% Trypsin-EDTA (Invitrogen) and incubated at 37°C for 10 min. The digestion process was stopped using DMEM containing 0.01% SBTI, 0.001% DNase and 0.075% BSA. For histology analysis, the brain and spinal cord were snap-frozen in liquid nitrogen and stored in −80°C until sectioning. The cryostat sections (20 µm) of lumbarsacral spinal cord or anterior, middle and posterior brain were fixed with 4% paraformaldehyde for 15 min and then stained with antibodies of interest, Blood vessels were visualized by anti-Flk-1 (VEGFR2, Sigma) and NSCs were stained with either anti-sox-2 (Millipore) or visualized by PKH26 dye in red. The spinal cords were then homogenized and the resulting pellets were resuspended in 0.25% Trypsin-EDTA (Invitrogen) and incubated at 37°C for 10 min. The digestion process was stopped using DMEM containing 0.01% SBTI, 0.001% DNase and 0.075% BSA. Blood vessels were visualized by Flk-1 (VEGFR2) staining.
Immunization for EAE induction and NSC/HSPC injection 
corresponding to mouse sequence is synthesized by QCB, Inc., Division of BioSource International (Hopkinton, MA), and purified to >99% by HPLC. Mice are immunized subcutaneously in the flanks with 150-200 µg of MOG peptide in 0.1 mL PBS and 0.1 mL CFA containing 0.4 mg Mycobacterium tuberculosis (H37Ra, Difco, Detroit, MI) and injected intraperitoneally with 200 ng Pertussis toxin (List Laboratories, Campbell, CA) on the day of immunization and 2 days later. EAE was scored in a blinded fashion; the investigator was not involved in the injections and was not aware of the composition of the groups. The following grade was used: Grade 1, limp tail or isolated weakness of gait without limp tail; Grade 2, partial hind leg paralysis; Grade 3, total hind leg or partial hind and front leg paralysis; Grade 4, total hind leg and partial front leg paralysis and Grade 5, moribund or dead animal. BT-NSC, GPS-NSCs, BT-HSPCs and GPS-HSPCs were injected as a cell suspension into the tail-vein of EAE mice in a volume of 0.2 mL of HBSS. Sham-treated mice (No NSCs) injected with HBSS alone were used as a negative control.
Immunohistologic staining
Mice were perfused with 50 mL normal saline before sacrificing to remove any intravascular peripheral blood mononuclear cells (PBMCs). For confocal imaging animals were perfused intracardially with 10 mL of 4% paraformaldehyde in PBS. The brain and the spinal cord were removed and embedded in optimal cutting temperature compound, quick frozen in liquid nitrogen and kept at −70°C until sectioning. Cryostat sections (10 µm) of spinal cords were fixed with acetone or 4% paraformaldehyde and then labeled with the antibody of interest. Isotype-matched Ig and omission of the primary antibody served as negative controls. Each specimen was evaluated at a minimum of three different levels of sectioning. The entire tissue section (a longitudinal spinal cord section) was evaluated for a given cellular marker at 40× magnification. The number of cells staining positive for the given markers was counted in ten 40× [high-power fields (HPFs)] fields per section. The results for one section were totaled, and the results between sections were averaged.
Staining for confocal microscopy
Paraformaldehyde-fixed sections (40 µm) were washed in PBS; blocked in PBS containing 4% goat serum, 0.3% BSA and 0.3% triton; and subsequently incubated with primary antibodies overnight and secondary antibodies for 2 h in blocking solution. We used highly cross-adsorbed secondary antibodies to avoid cross-reactivity (Alexa 488 and Alexa 594). Confocal microscopy was performed using a Zeiss Laser Scanning Microscope 3D analysis software (Zeiss, Thornwood, NY) with a multitrack acquisition protocol to avoid potential overlapping of the two fluorochromes.
Effects of GPS treatment on NSC differentiation, self-renewal capacity and immunosuppressive effects in vitro
The procedure for GPS treatment of murine NSCs was as previously described for MSCs . BT-and GPS-NSCs were compared in vitro for their capacity to self-renew, form neurospheres, differentiate into MAP2 + neurons and inhibit the proliferation of ConA activated lymph node cells. NSC differentiation and selfrenewal capacity: Neurospheres initially cultured in FGF/EGF containing media were plated on poly-D-lysine (PDL)-coated glass coverslips allowed to proliferate then harvested and treated for an hour with buffer (control) or enzymatic treatment with FTVI (60 mU/mL), subsequently the resulting BT-NSCs and GPS-NSCs were plated at clonal density of 20 cells per μL and allowed to proliferate as neurospheres for 96 h to 5 days. Neurosphere imaging was captured with an Axiovision microscope (NY, USA). For neuronal, astrocyte and oligodendrocyte differentiation, dissociated neurospheres were plated on PL-coated glass coverslips in a 24-well plate and cultured without FGF/EGF but in the presence of neurobasal medium containing 1% glutamax, 1% antibiotic/antimycotic and 2% B27 supplement. Fresh media was added every other day until Day 5, and the cells were then subjected to immunofluorescence staining with MAP2 (neurons), GFAP (astrocytes) and NG2 (oligodendrocyte precursors). MAP2 + , GFAP + and NG2 + cells were counted using standard stereological technique by an investigator blinded to the treatments. Co-cultures of Neural Stem Cells and Lymph Node Cells: Lymph nodes were isolated from naïve C57BL/6 mice. Lymph node cells (LNCs) were cultured as single-cell suspensions in a 96-well plate at 2 × 10 5 cells per well, as previously described (Einstein et al. 2007 ). Culture medium consisted of RPMI-1640 supplemented with 10% FBS, L-glutamine, sodium pyruvate, nonessential amino acid, 2-mercaptoethanol, HEPES and antibiotics (BioWhittaker, MD, USA) with 2.5 μg/mL concanavalin A (ConA, Sigma) or without. Neurospheres were dissociated and were first either treated with GPS or not (BT) and subsequently irradiated with 3000 Rad. Following irradiation, the dissociated NSCs were then added directly to the LNC culture medium at different ratios with ConA stimulated LNCs. The ratios tested of numbers of NSCs to numbers of LNCs were 1:4, 1:2, 1:1, 2:1 and 4:1. The cells were then cultured for 48 h before adding thymidine. Thymidine incorporation assays were performed 16 h later.
Assessment of E-selectin ligands following treatment of NSCs with inflammatory cytokines About 1.5 × 10 6 cells/well were seeded in a six-well plate containing 3 mL proliferation medium per well and stimulated with either 10 ng/mL of TNF-α (R&D; 410-TRNC), 10 ng/mL IL-1β (R&D; 401-ML) and 10 ng/mL IFNγ (R&D; 485-MI) independently or in combination (all three at 10 ng/mL). After 24 and 48 h, the neurospheres were harvested by centrifugation and stained with E-Ig for flow cytometric analysis.
Measurement of LIF mRNA
About 1 × 10 6 mouse embryonic NSCs were treated for 24 h with or without inflammatory cytokines (IFN-ϒ at 10 ng/mL and TNF-α at 15 ng/mL). Total RNA was then extracted using Trizol reagent, and the quality of the extracted RNA was measured using Agilent 2200 Tab station system. cDNA synthesis was done using high-capacity cDNA reverse transcription kit (Applied Biosystems) and a Random Hexamer. mRNA level was measured using reverse transcriptasepolymerase chain reaction (RT-PCR), and the fold change in gene expression was calculated using 2 −ΔΔCT method. The forward primer sequence for the LIF gene was CCTACCTGCGTCTTACTCCATCA and the reverse primer was CCCCAAAGGCTCAATGGTT (Sigma). The relative expression of LIF mRNA was assayed relative to glyceraldehyde 3-phosphate dehydrogenase housekeeping gene in which TGCAC CACCAACTGCTTAGC was used as a forward primer and GGCATG GACTGTGGTCATGAG as reverse primer.
Analysis of NSC migration to CNS
BT-NSCs and GPS-NSCs were labeled with PKH26 dye (Invitrogen) and injected intravenously into MOG-treated C57BL6 mice on Days 9 and 13 PI. One million NSCs were injected into each mouse on each day. HBSS buffer alone was used to determine background signals.
Either 24 h or 4 days after the second NSC transfer, mice were sacrificed, perfused and lumbar-sacral spinal cords were harvested. The spinal cord was chosen because in the B6 model, the CNS lesions in the forebrain are very variable in size and location compared with the spinal cords, which possess a more predictable location (lumbosacral region) and also more exuberant pathology (Chitnis et al. 2001; Rasmussen et al. 2007; Wang et al. 2008) . For flow cytometric analysis, the spinal cords were then homogenized and the resulting pellets were resuspended in 0.25% Trypsin-EDTA and incubated at 37°C for 10 min. The digestion process was stopped using DMEM containing 0.01% SBTI, 0.001% DNase and 0.075% BSA. For histology analysis, the brain and the spinal cord were snap-frozen in liquid nitrogen and stored in −80°C until sectioning. The cryostat sections (20 µm) of lumbar-sacral spinal cord or anterior, middle and posterior brain were fixed and then stained with antibodies of interest. Blood vessels were visualized by anti-Flk-1 (VEGFR2), and NSCs were stained with either anti-SOX-2 or visualized by PKH26 dye in red. For neuropathology analysis, cell quantification was performed by stereological analysis of animals in different groups. The spinal cords and the brain were sectioned, and every third section of the cervical and lumbosacral region was stained; cell quantification was performed in high-power magnification of 3-5 sections. LSM 510 Confocal microscope with motorized stage was used to stereologically calculate the intensity of staining and total cell numbers per high-power magnification.
Statistical analysis
Data are expressed as the mean ± SEM. 
